2012-2014 Master's in Public Health with Focus in Biostatistics, Harvard School of Public Health, Boston MA
1999-2004 Medical Doctorate with Distinction in Research, Albert Einstein College of Medicine, Bronx NY
1992-1996 Bachelor of Science - Chemistry, University of Idaho
2012-2013 Fellow in Research, Harvard School of Public Health, Boston MA
2011-2012 Interventional Pulmonary Fellow, Massachusetts General Hospital/Beth Israel Deaconess Medical Center, Boston MA
2009-2011 Pulmonary and Critical Care Fellow, Massachusetts General Hospital, Boston MA
2008-2009 Chief Medical Resident, Beth Israel Deaconess Medical Center, Boston MA
2005-2007 Resident, Internal Medicine, Beth Israel Deaconess Medical Center, Boston MA
2004-2005 Intern, Internal Medicine, Beth Israel Deaconess Medical Center, Boston MA
Our overarching goal is to improve the care of patients with known or suspected lung cancer who are undergoing advanced bronchoscopic procedures. In addition to my work as a Physician Scientist, I am an Interventional Pulmonologist with MPH training in clinical trial design and biostatistics. Our research program is comprised of a diverse highly collaborative, multidisciplinary research team that leverages biological, quantitative, and clinical sciences to address critical dilemmas within the lung cancer care pathway.
One of the primary pillars of our research laboratory is the investigation of intratumoral therapy for lung cancer. Specifically, our group is investigating the pharmacodynamics of bronchoscopic intratumoral delivery of cisplatin. The cisplatin is delivered under the guidance of endobronchial ultrasound (EBUS) and cone-beam CT scan, allowing us to precisely determine the delivery location for transbronchial needle injection (TBNI) into the tumor. Using radiomics image analysis, we recently demonstrated that measures of tumor density are better predictors of response to EBUS-TBNI cisplatin versus metrics of tumor morphology (J Thorac Dis). We also constructed a computational model based on tumor morphology based derived from the CT scan and cisplatin blood levels from a treated patient that predicts 5 injections may be superior to 1 for delivery of intratumoral cisplatin (Scientific Reports).
Our laboratory also utilizes quantitative image analysis and computational modeling to evaluate lung cancer risk, staging, and therapy. We recently leveraged data from the National Lung Screening Trial to evaluate the risk of mediastinal lymph node metastasis based on cancer location. By codifying location using a 3D Cartesian coordinate system, we were able to demonstrate that there is a significant risk of lung cancer metastasis even among peripheral T1 lesions (Chest).
Together, integrating clinical science, quantitative image analysis, and computational modeling we hope to make important strides forward for patients with lung cancer.
Ducomb EA, Tonellli BA, Tuo Y, Cole BF, Mori V, Bates JHT, Washko GR, San José Estépar R, Kinsey CM. “Evidence for Expanding Invasive Mediastinal Staging for Peripheral T1 Lung Tumors” Chest. 2020 Jun 26;. doi: 10.1016/j.chest.2020.05.607. [Epub ahead of print]. PMID: 32599066
Kinsey CM, San José Estépar R, Bates JHT, Cole BF, Washko GR, Jantz M, Mehta H. “Tumor Density is Associated with Response to Endobronchial Ultrasound-Guided Transbronchial Needle Injection of Cisplatin”. Accepted Journal of Thoracic Disease.
Folch EE, Mahajan AK, Oberg CL, Maldonado F, Toloza E, Krimsky WS, Oh S, Bowling MR, Benzaquen S, Kinsey CM, (25 additional authors). “Standardized Definitions of Bleeding After Transbronchial Lung Biopsy: A Delphi Consensus Statement From the Nashville Working Group.” Chest. S0012-3692(20)30272-5. PMID:32067944
Wahidi MM, Lamb C, Murgu S, Musani A, Shojaee S, Sachdeva A, Maldonado F, Mahmood K, Kinsey CM, Sethi S, Mahajan A, Majid A, Keyes C, Alraiyes AH, Sung A, Hsia D, Eapen G. American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients with Suspected or Confirmed COVID-19 Infection. J. Bronchology Interv Pulmonol. 18:10.1097 (2020). PMID: 32195687
Mahajan AK, Ost DE, Cole BF, Kinsey CM. Applications of Non-inferiority Trials in Interventional Pulmonology. J Bronchology Interv Pulmonol. 26(1):6-9.(2019). PMID: 30562280
Mori V, Roy GS, Bates JHT, Kinsey CM. “Cisplatin Pharmacodynamics Following Endobronchial Ultrasound Guided Transbronchial Needle Injection (EBUS-TBNI)”. Scientific Reports. 9(1): 6819 (2019). PMID 31048709
Kinsey CM and Ost D. “Randomization in Diagnostic and Therapeutic Interventional Pulmonary Trials”. Journal of Bronchology and Interventional Pulmonology. 23(4), 272–278. (2016). PMID 27764005
Kinsey CM and Arenberg DA. “Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Non-Small Cell Lung Cancer Staging”. Am J Respir Crit Care Med 189(6):640-649 (2014). PMID: 24598367.
Khan F, Garrison G, Anker C, and Kinsey CM. “Endobronchial ultrasound guided-transbronchial needle injection (EBUS-TBNI) for local control of recurrent non-small cell lung cancer”. Ann Am Thorac Soc 12(1):101-4 (2014) PMID: 25513850